as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2–positive breast cancer . J Clin Oncol 2012 ; 30 : 3792 – 3799 . 5. Bonneterre J Roché H Kerbrat P . Long-term cardiac follow-up in relapse
Search Results
Donna Trauth and Lori J. Goldstein
1998 ; 17 : 101 . 65 Eifel P Axelson JA Costa J . National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3 2000 . J Natl Cancer Inst 2001 ; 93 : 979 . www
David S. Ettinger
fusion gene EML-4 ALK . This mutation seems to be mutually exclusive with the EGFR and KRAS mutation in the phase I study. Adjuvant Therapy In 2004, the International Adjuvant Lung Cancer Trial showed an approximately 5% survival advantage
Ali Raza Khaki, V.K. Gadi, and Vinay Prasad
LA , Davis GJ , . Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer . J Clin Oncol 2001 ; 19 : 980 – 991 . 11181660 10.1200/JCO.2001.19.4.980 2. Wishart GC , Azzato EM , Greenberg
Justin Famoso, Gerald Lemole, Srinath Sundararajan, and Baldassarre Stea
should be tempered by maximal preservation of neurologic function. What does seem to be apparent is that STR without any adjuvant therapy is associated with a poor prognosis. There have been 16 cases presented in the literature that have undergone STR or
Ami Vyas, S. Suresh Madhavan, and Usha Sambamoorthi
months) after BC diagnosis constituted 37% of BC Medicare spending, which is substantially higher due to surgery and adjuvant therapy. 2 – 6 Additionally, elderly women aged ≥65 years have higher BC incidence compared with their younger counterparts, 7
Andrew L. Ji, Christopher K. Bichakjian, and Susan M. Swetter
predictor of survival and determines the indication for additional surgery (ie, complete lymph node dissection), systemic adjuvant therapy, surveillance imaging, and frequency of clinical follow-up. However, controversy remains regarding the most appropriate
Swaminathan Murugappan, William P. Harris, Christopher G. Willett, and Edward Lin
different benefits were seen from adjuvant therapy. 64 Patients were followed for a median of 4 years, with 41% of patients administered fluoropyrimidine-based adjuvant therapy. Patients with intermediate tumor response benefited the most from adjuvant
Efrat Dotan, Ilene Browner, Arti Hurria, and Crystal Denlinger
was sufficient to warrant consideration of adjuvant chemotherapy. Because cancer was found to be the primary cause of death in this population, adjuvant therapy is likely to improve disease outcomes. The lower rates of adjuvant therapy use among
03689712) is in progress. Clinical trials to reduce RT-related esophagitis are also planned. CLO19-040: The Role of Adjuvant Therapy in Patients With Pathological T2N0 Resected Gastric Adenocarcinoma John Khoury, MD a ; David Macari, MD a ; Daniel Ezekwudo
